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Introduction 
The use of performance-enhancing substances by athletes is as old as sport itself. However, over the 
past decade, concern has grown as the use of a wide variety of drugs being used — in particular 
anabolic steroids and growth hormone — has transcended the elite sporting arena to the general 
population where they are used for both performance- and image-enhancing reasons. However, 
even for the most commonly used and best known of the substances, anabolic steroids, there is a 
paucity of reliable information as to the prevalence of use. Current mechanisms for monitoring the 
levels of use are inadequate (Advisory Council on the Misuse of Drugs, 2010). The Crime Survey for 
England & Wales (CSEW), the mainstay of identifying levels of drug use in the population, estimates 
that for England and Wales in 2013/14 were, for lifetime use, 262,000 ( range 217,000 – 308,000) 
and for use in the previous 12 months, 66,000 (range 43,000 -  89,000). However, data over time 
from CSEW (and its forerunner, the British Crime Survey) would indicate that there has been no 
increase in anabolic steroid use, in fact a decrease since 1996. In 1996, a lifetime prevalence of 1.1% 
was identified, decreasing to 0.5% in 2004 before returning to 0.8% in 2013/14. However, data from 
needle and syringe programmes contradict these findings, with these estimates largely accepted as 
underestimates (National Institute for Health and Care Excellence, 2014; Bates et al, 2014; McVeigh 
et al, 2003; McVeigh et al, 2007). 
This group of drug users, referred to as steroid and image enhancing drugs (SIEDs) users presents a 
number of specific challenges for healthcare services; they are injecting drug users who frequently 
employ very complex drug regimens with no evidential basis. In recent years we have witnessed a 
rapid expansion of substances used, with an array of prescription only medicines being used in 
tandem with peptide hormones which are still at the early stages of development. The drugs are 
predominantly illicitly manufactured and sourced (Larance et al, 2005; Parkinson et al, 2006; Striegal 
et al, 2006), although legal to possess for personal use. They are of highly variable quality and 
sterility and pose a significant health risk to the user (Graham et al, 2009; Evans-Brown et al, 2009; 
Stensballe et al, 2014; Breindahl et al, 2014; Kimergård et al 2014a; Kimergård et al 2014b).  
Alongside use of SIEDs, there is also evidence of the concurrent use of psychoactive drugs, especially 
cocaine and cannabis (Hope et al, 2013; Sagoe et al, 2015). As well as these issues there are many 
adverse health conditions specifically associated with the use of SIEDs. Anabolic steroids alone have 
been linked with adverse effects from acne, accelerated balding, gynaecomastia, sexual dysfunction, 
mood and psychological effects to a growing body of evidence of serious chronic conditions, in 
particular those associated with cardiac physiology and function (Pope et al, 2014). As new drugs are 
added to the existing array of pharmacological substances, the potential for harm increases and 
becomes more diverse.  
The most significant threat to this population lies in the risks associated with injecting. Historically, 
the issue of blood borne virus transmission has largely been dismissed (Crampin et al, 1998), 
although risk behaviour amongst populations of SIEDs users has been identified (Midgeley et al, 
2000; Kimergard & McVeigh, 2014a). Findings from the largest study of blood-borne viruses among 
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SIED injectors, conducted across England and Wales in 2010-2011 (Hope et al, 2013) illustrated HIV 
prevalence at a similar level to those injecting psychoactive drugs such as heroin and cocaine. These 
findings were confirmed in the unlinked anonymous HIV and viral hepatitis monitoring among 
people who inject drugs in 2012-13. Of the 249 participations in the 2012-13 survey across England 
and Wales, 2.0% (95% CI, 0.74%-4.9%) had HIV, 2.8% (95% CI, 1.2%-5.9%) anti-HBc and 3.6% (95% CI, 
1.8%-7.9%) anti-HCV. Although the prevalence of antibodies to both hepatitis B and C were lower 
than levels observed amongst participants in the main survey, targeted at people who inject 
psychoactive drugs, the prevalence of HIV is similar in both of the surveys. The survey also identified 
a highly sexually active population with low rates of condom use (Public Health England, 2014). 
Additionally, injection site problems were common, being reported by over a third of participants in 
the study conducted in 2010-2011 (Hope et al, 2015). 
The public health concerns related to this population are exacerbated by an apparent reluctance of 
many SIED users to engage with health and support services, in particular primary care. Injectors 
experiencing injecting related injuries are most likely to self-treat conditions as they arise, resorting 
to attendance at Accident & Emergency Departments in the event of increasing severity (Hope et al, 
2015). During in depth interviews SIED injectors have cited a lack of trust and confidence in the 
treatment that they would expect within primary care settings (Kimergard & McVeigh, 2014b). 
In order to better understand and evidence the public health issues acknowledged above, Public 
Health Wales commissioned an online survey of SIED users in the UK, in collaboration with academic 
colleagues at the Centre for Public Health, Liverpool John Moores University. This document 
summarises key findings from the second year of the SIEDs survey, with a particular focus of the 
report being on the specific drugs of use. The report also outlines the further dissemination of 
results from the 2014 data sweep of the survey and describes developments for enhanced data 
collection in 2015. These summary findings from the 2014 survey should be viewed in conjunction 
with the 2013 survey results (Chandler & McVeigh, 2014), which can be downloaded at:  
http://www.cph.org.uk/wp-content/uploads/2014/06/Steroids-and-Image-Steroid-Image-
Enhancing-Drugs-2013-Survey-Results-FINAL.pdf  
Survey Methods 
The original survey, conducted in 2013, comprised 51 questions exploring the use of SIEDs. In 
response to issues raised within the first survey; 6 questions exploring the participants’ most recent 
cycle in greater detail were added for 2014. The survey was constructed using the Bristol Online 
Survey Tool (BOS). This is an online resource made available to Universities across the UK and widely 
used in research (http://www.survey.bris.ac.uk). Ethical approval for the survey was obtained via the 
Liverpool John Moores University Research Ethics Committee.  
The survey was drafted by the Centre for Public Health at Liverpool John Moores University and 
subsequently refined following feedback from research partners. Following completion of ethical 
approval and review, the survey link initially went live on 10th July 2013 and was closed at midnight 
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on the 12th November 2013. This second run of the survey went live on the 6th June 2014 and 
formally closed at midnight on the 30th September 2014.  
The online survey was disseminated via the most popular UK–based online forums dedicated to 
weight training and/or the use of SIEDs (UK-Muscle, Testosterone Muscle, Muscle Talk and 
Underground Muscle) and via NSPs engaging with SIED users. We also provided paper versions of 
the survey for participants to complete when visiting NSPs, for those people who did not wish to 
complete them online.  
 
 
Key findings 
Description of the sample 
A total of 108 people from the UK took part in the survey; of which 8 (7%) were female. A third 
(33%) of respondents were from Wales, with 59% from England and 7% from Scotland and the vast 
majority (89%) described their ethnicity as White British. All published work dating back to the early 
to mid-1990s has supported the assertion the majority of SIED users are White British (Korkia & 
Stimson, 1993; Lenehan et al, 2006; Lenehan & McVeigh, 1998). However, recently published 
qualitative work in the United Kingdom has identified a significant group of British South Asian SIED 
users with specific needs and requiring purposeful engagement (van Hout & Kean, 2015).  
Participants in this survey were aged between 17 and 64 years of age, with a mean age of 33 years, a 
considerably younger cohort than those injecting psychoactive substances such as heroin and crack 
cocaine (Whitfield et al. 2014) (see Table 2 for data relating to age of first use of SIEDS). 
SIED use 
Participants described their primary purpose and other motivations for using SIEDs (Table 1). The 
most commonly reported motivations included gaining muscle and strength together with losing fat. 
For over half of participants (59%) the primary goal of their SIED use was to gain muscle, with a 
further 15% citing fat loss as the main motivation for use. Superficially, these primary motivations 
have remained largely unchanged from the early exploratory research of the 1990s. A total of 386 
anabolic steroid users interviewed in the North West of England stated their main purposes of use as 
improve bodybuilding and increase muscle (Lenehan et al, 2006). However, there are significant 
differences between anabolic steroid users identified in the 1990s compared to the population of 
SIED users today who are not a homogenous group. The characteristics of SIED users are more 
diverse than in the past and the perceived benefits of using enhancement drugs are equally 
disparate. This is reflected in the vast array of substances which fall under the category of SIEDs.  
For a quarter of those sampled, an increase in sex drive was a motivation for use, while relatively 
high numbers of individuals highlighted the benefits of a getting a suntan or enhancing the skin (for 
those injecting melanotan I and melanotan II). While few individuals highlighted these as their 
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primary purpose of use, it reflects the complex drivers related to this broad category of drug use and 
the issue of polypharmacy. The issue of polypharmacy, both in terms of enhancement drugs (see 
tables 3 and 4) and recreational or psychoactive substance use (see table 5), is not restricted to the 
United Kingdom and is seen as a growing global public health concern (Sagoe et al, 2015).  
Table 1: Motivations for SIED use (n=108) 
 n (%) Main goal n (%) 
To gain muscle 98 (90.7) 64 (59.3) 
To lose fat 78 (72.2) 16 (14.8) 
To get stronger 89 (82.4) 12 (11.1) 
To get fitter 52 (48.1) 2 (1.9) 
To get faster 31 (28.7) 0 
To improve endurance or stamina 39 (36.1) 2 (1.9) 
To get a tan 22 (20.4) 2 (1.9) 
To reduce wrinkles or improve skin 12 (11.1) 1 (0.9) 
To increase sex drive 28 (25.9) 1 (0.9) 
Did not answer - 8 (7.4) 
 
The vast majority of participants reported taking SIEDs both orally (n=99, 92%) and through an 
injection (n=94, 87%), with this finding being common to most SIED related research. There were 
some differences in reported age of first SIED use, depending on method of use (Table 2). More 
specifically, findings suggest that onset of oral consumption of SIEDs is likely to be slightly earlier 
than use of injectable substances. One third (33%) of the sample reported first use of oral SIEDs by 
21 years of age, including 9% initiating use by age 18. In comparison approximately one quarter 
(27%) of participants reported first injecting SIEDs by 21 years of age including 6% by age 18. Age of 
initiation of SIED use is typically reported to be before age 30 and may be as early as age 14 (Sagoe 
et al, 2014). The difference in age of initiation of SIED use by method of administration is smaller 
than has been identified in a number of previously published United Kingdom research studies (for 
example, Korkia & Stimson, 1993; Lenehan et al, 1996). The explanation for this is unproven as yet 
but could be associated with a greater knowledge of liver damage caused by oral anabolic steroids or 
the increasing number of products that are only available in injection formula, for instance 
melanotan II and a number of anabolic peptide hormones.  
Table 2: Age of SIED initiation by method of use (n=108) 
 Injection n (%) Oral n (%) 
21 and under 29 (26.9) 36 (33.3) 
22 – 25 24 (22.2) 26 (24.1) 
26 – 30 19 (17.6) 15 (13.9) 
31 and over 22 (20.4) 19 (17.6) 
Did not answer 14 (13.0) 12 (11.1) 
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Participants described their average and most recent SIED cycles. Almost all cycles reported 
employed both injectable and oral anabolic steroids simultaneously, sometimes in conjunction with 
a range of other SIEDs, including weight loss agents, peptide hormones and cosmetic enhancers (e.g. 
tanning agents). The average cycle length for injectable steroids was 20 weeks; however 29 (27%) 
stated they used a “Blast and Cruise” approach, whereby a smaller dose is injected for a period of 
weeks (the ‘Cruise’) alternated with larger doses as per a normal cycle (the ‘Blast’). The longest 
injectable cycle reported was four years and ongoing. The average cycle length for oral anabolic 
steroids was 9 weeks; the longest was three years and ongoing. 
For the 2014 survey, a section was introduced asking detailed questions about the most recent (or 
current) cycle; including questions around dose. The mean dose for injectable anabolic steroids was 
approximately 1.5 grams per week, with the largest dose being 7.5 grams per week. A total of 77 
participants reported their weekly dose and of these, 46 were employing doses of 1 gram or more. 
To put this in perspective; natural testosterone production is approximately 49-77 milligrams per 
week (Llewellyn, 2009). 
Substances used 
People who use SIEDs commonly report use of a range of other substances typically used to enhance 
the impact of their steroid use, to counter side effects, for recreational or relaxation and sexual 
enhancement (Sagoe et al, 2015). Additional substances used by people who use anabolic steroids 
have been classified into 13 groups: analgesics/non-steroidal anti-inflammatory drugs/opioids, anti-
oestrogens, cardiovascular drugs, central nervous system depressants, central nervous system 
stimulants, cosmetic drugs, dietary/ nutritional supplements, diuretics, fat burning/weight loss 
drugs, muscle/strength-enhancement hormones, non-hormone muscle/strength-enhancement 
drugs, recreational substances/drugs, and sexual enhancement drugs (Sagoe et al, 2015). 
Table 3: Recent and lifetime use of oral SIEDs (n=99) 
 Past year n (%) Lifetime n (%) 
Anabolic steroids 64 (64.6) 93 (93.9) 
Nolvadex 57 (57.6) 75 (75.8) 
Aromatase Inhibitor 46 (46.5) 54 (54.5) 
Viagra/ Cialis 44 (44.4) 58 (58.6) 
Clomid 33 (33.3) 57 (57.6) 
Clenbuterol 28 (28.3) 45 (47.8) 
Thyroid hormones 27 (27.2) 35 (35.3) 
Ephedrine 23 (23.2) 49 (49.5) 
Prohormones/ designer steroids 16 (16.2) 28 (28.3) 
Diuretics 11 (11.1) 14 (14.1) 
DNP 8 (8.1) 15 (15.2) 
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Oral SIEDs 
Use of oral SIEDs amongst 99 participants who consumed their SIEDs orally (n=99) is reported in 
Table 3. The most commonly used substances taken orally in the past year were anabolic steroids 
(65%), Nolvadex (58%), Aromatase Inhibitor (47%) and Viagra/Cialis (44%).  
 
Injectable SIEDs 
Amongst participants who injected SIEDs (n=94), nearly two thirds (64%) stated that they had 
injected testosterone enanthate in the past year with use of a range of other anabolic steroids 
reported by smaller proportions of the sample (Table 4). Approximately one fifth of these 
participants reported recent use of Human Growth Hormone (19%) and 16% reported they had used 
tanning agents Melanotan I or II (16%). 
 
Table 4: Recent and lifetime use of injectable SIEDs (n=94) 
 Past year n (%) Ever n (%) 
Testosterone enanthate 60 (63.8) 75 (79.8) 
Sustanon 43 (45.7) 67 (71.3) 
Testosterone propionate 38 (40.4) 53 (56.4) 
Deca-Durabolin 36 (38.3) 64 (68.1) 
Underground lab blend 34 (36.1) 46 (49.9) 
Trenbolone acetate 33 (35.1) 44 (46.8) 
Testosterone cypionate 30 (31.9) 49 (52.1) 
Masteron 27 (28.7) 35 (37.2) 
Trenbolone enanthate 25 (26.6) 39 (41.5) 
Equipoise 25 (26.6) 37 (39.4) 
hCG 22 (23.4) 29 (30.9) 
Human growth hormone 18 (19.1) 35 (37.2) 
Melanotan I or II 15 (16.0) 21 (22.3) 
Winstrol 11 (11.7) 24 (25.5) 
Testosterone suspension 9 (9.6) 14 (14.9) 
Insulin 9 (9.6) 14 (14.9) 
GHRP 6 (6.4) 17 (18.1) 
IGF 3 (31.9) 12 (12.8) 
MGF 2 (2.1) 6 (6.4) 
 
Other substance use 
Participants were asked about their use of psychoactive drugs (Table 5) and alcohol consumption.  
While substantial proportions of participants reported lifetime use of a range of psychoactive drugs, 
less than one third of the sample (32%) reported use of any psychoactive drug in the previous year; 
the most commonly reported substances being cannabis (15%) and cocaine (10%). This is a 
considerably lower level of cocaine use compared to other studies of psychoactive drug use amongst 
users of SIEDS. In Hope et al’s study (2013), 46% of the 395 male SIED users had snorted cocaine in 
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the previous 12 months. This difference may be caused by the different recruitment approach, with 
a high proportion of Hope’s sample derived from needle and syringe programmes compared to 
significant recruitment from online forums in this current study. A small minority reported injecting 
any psychoactive drug in the past year (4%) or in their lifetime (7%). People who use SIEDs report 
lifetime use of a range of other recreational substances, prominently including alcohol, 
amphetamines, cannabis and cocaine, and frequently report use of a variety of these substances 
alongside their SIED use (Sagoe et al, 2015). On average, alcohol consumption was relatively low in 
this sample with nearly two thirds (64%) reporting that they consumed alcohol on a monthly or less 
basis. Heavier drinking, including consuming six or more drinks in one day on a weekly basis and 
consuming alcohol on two or more days a week, was reported by around 15% of the sample.  
Similar to findings from the previous year (Chandler & McVeigh, 2014), a minority of participants are 
using these substances to potentially harmful levels and therefore increasing the risks associated 
with both SIEDs and drugs and alcohol. For example, the use of alcohol (Rehm et al, 2010) and oral 
anabolic steroids (Pope et al, 2013) are associated with adverse effects within the liver and both 
psychoactive drugs (Fletcher et al, 2010) and anabolic steroids (Pope et al, 2013) are associated with 
the onset of mental health issues, although the evidence for this relationship between anabolic 
steroids and psychological issues is inconclusive.   
Table 5: Recent and lifetime use of psychoactive substances 
 Past year n (%) Lifetime n (%) 
Cannabis (n=94) 27 (14.8) 68 (63.0) 
Cocaine (n=92) 26 (10.2) 55 (51.0) 
Ecstasy (n=92) 13 (.3) 54 (50.0) 
Speed (n=92) 11 (9.3) 48 (44.4) 
Ketamine (n=80) 5 (3.7) 20 (18.5) 
Mephedrone (n=77) 5 (2.8) 16 (14.8) 
Poppers (n=83) 4 (3.7) 35 (42.2) 
Crack (n=77) 2 (1.9) 7 (6.5) 
GHB (n=79) 1 (0.9) 12 (11.1) 
Heroin (n=75) 1 (0.9) 6 (5.6) 
 
Polypharmacy associated with SIED use has been linked to a range of negative outcomes, including 
violence, criminal behaviour, illness and mortality (Sagoe et al, 2015). The use of illicit drugs exposes 
individuals to a range of harms associated with substance misuse, including from contaminated 
drugs, psychological and physiological effects and, where substances are injected, injection site 
injuries and infections and potential transmission of blood-borne viruses.  
Adverse effects from SIED use 
A range of harmful physiological and psychological effects have been linked to use of anabolic 
steroids. There is some evidence that steroid use may be associated with increased risk of 
cardiovascular effects, including cardiomyopathy, myocardial infarction and other harms such as 
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metabolic, neurologic, renal and musculoskeletal disorders (Pope et al, 2014). Use of steroids 
amongst younger people may have long-term harms due to their impact on patterns of growth. 
Amongst females there is also an increased risk of a range of significant and potentially permanent 
physical effects including the development of male characteristics, such as deepening of the voice 
and abnormal hair growth (Advisory Council on the Misuse of Drugs, 2010). Steroid use has 
additionally been linked with psychological impacts, including aggression, depression and mania 
(Advisory Council on the Misuse of Drugs, 2010). However there is a lack of conclusive evidence and 
while studies suggest that individuals using steroids may display a range of symptoms relating to 
mood disorders, these vary greatly by individual cases and symptoms are rarely severe (Pope et al, 
2014).  
Table 6: Injuries and adverse side-effects associated with SIED use (n=108) 
 Past Year n (%) Ever n (%) 
Testicular atrophy 54 (50.0) 65 (50.6) 
Pain at injection site  47 (43.5) 55 (50.9) 
Swelling, redness or heat at injection site  29 (26.9) 39 (36.1) 
Raised blood pressure 28 (25.9) 41 (38.0) 
Gynaecomastia 21 (19.4) 35 (32.4) 
Increased aggression/ irritability 21 (19.4) 33 (30.6) 
Mood swings 20 (18.5) 28 (25.9) 
Unwanted facial or body hair 15 (13.9) 20 (18.5) 
Hair loss 13 (12.0) 17 (15.7) 
Nausea 11 (10.2) 13 (12.0) 
Deepening of voice 6 (5.6) 6 (5.6) 
Abscess, sore or open wound at injection site  1 (0.9) 11 (10.2) 
Survey participants described adverse side-effects that they attributed to their SIED use (Table 6) 
with 70% reporting experiencing any injury or side-effects in the previous year. The most commonly 
reported lifetime adverse effects were physical symptoms, including testicular atrophy (51%), pain at 
the injection site (51%), raised blood pressure (38%) and swelling, redness or heat at the injection 
site (36%). A smaller but substantial proportion of participants reported ever experiencing adverse 
psychological effects such as increased aggression or irritability (31%) and mood swings (26%). When 
asked how they responded to these adverse effects, 49 participants (45%) reported waiting for some 
side-effects to go away on their own and 46 (43%) reported treating some themselves. Frequently 
the self-treatment employed either natural remedies and/or other pharmaceutical drugs (for 
example, the use of tamoxifen to reduce gynaecomastia or the use of celery seed to reduce high 
blood pressure). A minority of participants (6%) reported being treated by their GP or in other 
healthcare settings including A&E (5%). 
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Injecting behaviours and Blood Borne Viruses  
Table 7: Frequency of injecting SIEDs by injection method (n=94) 
 
 
 
 
 
Frequency of injecting SIEDs is reported in Table 7. Participants were most likely to inject 
intramuscularly on approximately 2-4 days per week with small numbers injecting on a daily basis or 
greater. Over two thirds of those injecting SIEDs reported that they did not inject subcutaneously, 
but 14% stated that they did so on a daily basis or greater. Place of injection is reported in Table 8; 
the most frequently reported places to inject were the gluteus, quadriceps and deltoid sites.  
Table 8: Injection sites by injection method (n=94) 
 Intramuscular 
injection 
n (%) 
Subcutaneous 
injection 
n (%) 
Gluteus 70 (74.5) 0 
Quadriceps  51 (54.3) 2 (2.1) 
Deltoid 42 (44.7) 0 
Triceps 11 (11.7) 0 
Biceps 9 (9.6) 0 
Pectoral 7 (7.4) 0 
Abdomen 4 (4.3)  19 (20.2) 
Latissimus dorsi 2 (2.1) 0 
Evidence from a study in England and Wales suggests a similar prevalence rate for HIV (2%) amongst 
individuals injecting SIEDs to those injecting psychoactive drugs (Public Health England, 2014). 
Findings also suggest that less than half of SIED users may have undergone testing for HIV (41%) or 
hepatitis C (32%), or reported uptake of the hepatitis B vaccine (40%). Similar findings were 
identified in our survey where all participants were asked about their blood borne virus (BBV) testing 
history, with over half the sample reporting that they had never undergone testing for any BBV 
(table 9). Additionally, fewer than half (44%) had received vaccinations for Hepatitis B. 
Of 94 survey participants who had ever injected SIEDs, two thirds (67%) reported using a needle and 
syringe programme to obtain injecting equipment in the previous year and over one quarter (28%) 
reported acquiring their injecting equipment over the internet. Other methods included obtaining 
equipment from a SIED supplier (3%) or friend (4%). Of all ever injectors, 10% reported ever re-using 
 Intramuscular 
injection 
n (%) 
Subcutaneous 
injection 
n (%) 
More than once per day 2 (2.1) 2 (2.1) 
Daily 7 (7.4) 11 (11.7) 
Every other day 28 (29.8) 4 (4.3) 
Twice per week 34 (36.2) 2 (2.1) 
Once per week 16 (17.0) 3 (3.2) 
Less than once per week 2 (2.1) 5 (5.3) 
Never 0 62 (68.1) 
Did not answer 5 (5.3) 5 (5.3) 
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their own equipment and generally not at all or infrequently in the previous 12 months; no injectors 
reported ever using equipment ever used by another individual. A small proportion (7%) reported 
ever sharing a multi-dose vial with another individual. The low rate of sharing equipment is in line 
with other research with SIED users, for example findings from PHE’s unlinked anonymous survey 
suggest lifetime injection equipment sharing at 13% (Public Health England, 2014) and previous 
studies suggest rate of sharing amongst this population at between 0 and 20% (Advisory Council on 
the Misuse of Drugs, 2010). 
Table 9: Blood borne virus vaccination and testing status (n=108) 
 n (%) 
Ever vaccinated Hep B 47 (43.5) 
Ever tested Hep B 46 (42.6) 
Ever tested Hep C 47 (43.5) 
Ever tested HIV 41 (38.0) 
Conclusion 
The findings from this survey build upon the results described in the 2013 survey report (Chandler 
and McVeigh, 2014). There is a clear need to routinely investigate the drug use and related 
behaviours and health outcomes amongst SIED using populations. The SIEDs market is dynamic and 
fast moving, with the practices and preferences of the population constantly changing along with the 
associated risks to health. Evidence suggests that SIED users form a heterogeneous population, with 
different motivations, needs and drug use behaviours, for example as highlighted by the range of 
SIEDs injected and taken orally reported here. Further research and increased understanding of the 
sub groups that make up SIED using population is essential for the development of effective 
prevention, harm reduction and treatment interventions. For example, the findings reported here 
suggest that it is important to understand how to better engage SIED users with health services for 
the treatment of adverse health effects associated with their SIED use, and to identify effective 
approaches to increase testing for blood borne viruses amongst this population.  
Next steps 
To raise the profile of this survey to aid dissemination of findings and to promote the 2015 survey, 
an additional output in the form on an infographics poster will be produced. The poster will highlight 
key findings discussed within this report in a visually compelling and easily accessible format. 
To build upon and expand the data already collected, the next version of this survey will run from 
August to December 2015. To substantially increase the number of participants, additional methods 
of recruitment will be utilised for the 2015 data collection. This will include a greater focus on SIED 
users who may not be engaged with health and drug related services, or those participating via 
online discussion forums. For example, data collection in gym and fitness settings will be take place.  
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